Last reviewed · How we verify
NCT03320980
RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma
trial testing RALPPS in Hilar Cholangiocarcinoma in 30 participants. Completed in 1 October 2017.
20 September 2017
Quick facts
| Lead sponsor | Moscow Clinical Scientific Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 15 September 2014 |
| Primary completion | 20 September 2017 |
| Estimated completion | 1 October 2017 |
Drugs / interventions tested
- RALPPS
- portal vein embolization + major liver resection
Conditions studied
- Hilar Cholangiocarcinoma — all drugs for Hilar Cholangiocarcinoma →
- Intrahepatic Cholangiocarcinoma — all drugs for Intrahepatic Cholangiocarcinoma →
Sponsor
Moscow Clinical Scientific Center
Who can join
Adults 18 to 80, any sex, with Hilar Cholangiocarcinoma or Intrahepatic Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Unsatisfactory immediate outcomes of Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in surgery of cholangiocarcinoma suggested that patients with biliary cancer should not be treated by ALPPS. Short-term results of ALPPS variants with reduced surgical trauma on the first stage in patients with cholangiocarcinoma were not yet estimated. The objective of the study was estimation of the short-term results of split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage (RALPPS) in patients with hilar (h-CCA) and intrahepatic (i-CCA) cholangiocarcinoma compared with portal vein embolization (PVE).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03320980
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hilar Cholangiocarcinoma
Currently open trials in the same condition.
- NCT06717464 — Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepa · Phase 2 · active not recruiting
- NCT07176962 — A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening · recruiting
Other Moscow Clinical Scientific Center trials
Trials by the same sponsor.
- NCT05775107 — Pancreatic Fibrosis as a Prognostic Factor · unknown
- NCT05775120 — Epidemiology of Helicobacter Pylori Infection in Moscow · unknown
- NCT04800393 — The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breas · NA · recruiting
- NCT04905329 — A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer P · unknown
- NCT03683537 — Association Between Changes of GFAP After Surgery and Postoperative Delayed Cognitive Recovery · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03320980 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Moscow Clinical Scientific Center
- Last refreshed: 25 October 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03320980.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing